Although GvHD can sometimes be diagnosed based on symptoms alone, other cases are not so straightforward. In cases like these ...

During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...

The addition of post-transplant cyclophosphamide to sirolimus and cyclosporine reduced chronic GVHD. Efforts are needed to optimize cyclophosphamide dose to reduce toxicity. A novel regimen ...

chronic GVHD including overall and moderate/severe chronic GVHD per National Institutes of Health (NIH) criteria, 37 neutrophil and platelet engraftment, donor chimerism assessments, incidence of ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...